Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Obinutuzumab in Untreated Follicular Lymphoma
NCT05387616Phase 2Active, not recruiting
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in follicular lymphoma (FL), sponsored by Ludwig Maximilian University of Munich. Started Oct 2020; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05387616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387616.